A dosage-form platform is the beginning of a sterile injectable discussion, not the conclusion. A responsible CMO/CDMO assessment tests whether the proposed product, process, facility, analytical package, registration path and supply model can operate together under an agreed quality system.
Public platform scope
CMO, CDMO and transfer pathways
CMO: project-specific commercial manufacturing for a sufficiently mature and transferable product. CDMO: development and manufacturing work that may include formulation, process, analytical, scale-up or registration-support activities within an agreed scope. Technology transfer: controlled transfer of product, process, method and supporting knowledge to a receiving unit.
These descriptions are cooperation pathways, not unconditional service guarantees. The exact package depends on current resources, product maturity, technical fit, applicable production authorization and target-market requirements.
What determines project fit
- dosage form, active and formulation characteristics;
- sterilization or aseptic-processing strategy;
- presentation, container-closure system and batch size;
- development, validation and commercial history;
- analytical methods, microbiological testing and stability package;
- target market, dossier status and required regulatory change;
- forecast, campaign model, release route and desired timing;
- quality, data, intellectual-property and supply responsibilities.
Stage-gated cooperation route
Review non-confidential product, market, stage and timing information.
Agree controlled use and access before confidential technical exchange.
Map technical, quality, regulatory, supply and commercial gaps.
Define deliverables, evidence, owners, acceptance criteria, cost and schedule.
Execute controlled development, method, engineering and validation work.
Confirm registration, release, supply and lifecycle governance.
Initial information to provide
Dosage form, target market, project stage, intended cooperation model, desired timing, presentation and a short non-confidential objective are sufficient for a first screen. Do not send patient information, prescriptions, complete formulations, detailed process instructions, unpublished dossiers or other trade secrets before a mutual NDA.
Read the full project-evaluation framework →
Authoritative references
This page supports general institution-to-institution business discussion. It is not medical, legal or regulatory advice and does not replace official corporate channels. Project requirements must be confirmed against current records and applicable requirements.